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Inﬂuence of the glycocalyx and plasma membrane
composition on amphiphilic gold nanoparticle
association with erythrocytes†
Prabhani U. Atukorale,a Yu-Sang Yang,b Ahmet Bekdemir,c Randy P. Carney,c
Paulo J. Silva,c Nicki Watson,d Francesco Stellaccic and Darrell J. Irvine*a,b,e,f,g,h
Erythrocytes are attractive as potential cell-based drug carriers because of their abundance and long life-
span in vivo. Existing methods for loading drug cargos into erythrocytes include hypotonic treatments,
electroporation, and covalent attachment onto the membrane, all of which require ex vivo manipulation.
Here, we characterized the properties of amphiphilic gold nanoparticles (amph-AuNPs), comprised of a
∼2.3 nm gold core and an amphiphilic ligand shell, which are able to embed spontaneously within
erythrocyte membranes and might provide a means to load drugs into red blood cells (RBCs) directly
in vivo. Particle interaction with RBC membranes occurred rapidly at physiological temperature. We further
show that amph-AuNP uptake by RBCs was limited by the glycocalyx and was particularly inﬂuenced by
sialic acids on cell surface proteoglycans. Using a reductionist model membrane system with synthetic lipid
vesicles, we conﬁrmed the importance of membrane ﬂuidity and the glycocalyx in regulating amph-AuNP/
membrane interactions. These results thus provide evidence for the interaction of amph-AuNPs with eryth-
rocyte membranes and identify key membrane components that govern this interaction, providing a frame-
work for the development of amph-AuNP-carrying erythrocyte ‘pharmacytes’ in vivo.
Introduction
Targeting erythrocytes (red blood cells, or RBCs) as cellular
carriers of therapeutic drug molecules has been of interest for
many years. Erythrocytes are highly attractive as potential
‘pharmacytes’ for several key reasons.1,2 They are the most
abundant cells in the body and are readily available; humans
have ∼2.5 × 1013 erythrocytes, produced constantly at a rate of
2 million cells per second. They have a long ∼120-day lifespan
in circulation, and this feature can be exploited in applications
where slow and sustained cargo release into the intravenous
circulation is desired. For example, erythrocytes have been
used as circulating depots of vitamins3 and steroids,4–7 agents
for antineoplastic,8–10 antiparasitic,11–13 and antiretroviral14–20
therapies, and also as carriers for cardiovascular
therapeutics.21–23 Erythrocyte carriers are intrinsically bio-
degradable without the generation of toxic byproducts. They
are cleared by macrophages in the reticuloendothelial system
of the liver and spleen. As autologous cell-based cargo carriers,
RBCs have the advantage of being bio-inert, with no risk of
triggering an immune response. Finally, from a practical/trans-
lational perspective, they can also be readily manipulated
ex vivo and stored stably at 4 °C.
Despite these attractive properties, the requirement of
ex vivo manipulation is a significant disadvantage of cell-based
therapies in general, because this extra step can be both cum-
bersome and expensive. Because erythrocytes are non-endo-
cytic and many cargo materials cannot interact with or
penetrate their plasma membranes, techniques of cargo
encapsulation in RBCs typically rely on mechanisms of mem-
brane perturbation that force cargo molecules into the cell
cytosol. Hypotonic treatments have often been used to encap-
sulate cargoes into erythrocytes.24–27 Electroporation is
another widely used technique, particularly for large molecular
weight or highly charged cargoes that cannot passively transit
†Electronic supplementary information (ESI) available. See DOI: 10.1039/
c5nr01355k
aDepartment of Biological Engineering, Massachusetts Institute of Technology,
Cambridge, Massachusetts 01239, USA. E-mail: djirvine@mit.edu
bDepartment of Materials Science and Engineering, Massachusetts Institute of
Technology, Cambridge, Massachusetts 01239, USA
cInstitute of Materials, Ecole Polytechnique Federale de Laussane, 1015 Lausanne,
Switzerland
dWhitehead Institute for Biomedical Research, Cambridge, Massachusetts 01239,
USA
eInstitute for Soldier Nanotechnologies, Massachusetts Institute of Technology,
Cambridge, Massachusetts 01239, USA
fKoch Institute for Integrative Cancer Research, Massachusetts Institute of
Technology, Cambridge, Massachusetts 01239, USA
gRagon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts 02139, USA
hHoward Hughes Medical Institute, Chevy Chase, Maryland 20815, USA
This journal is © The Royal Society of Chemistry 2015 Nanoscale
Pu
bl
ish
ed
 o
n 
09
 Ju
ne
 2
01
5.
 D
ow
nl
oa
de
d 
by
 C
A
SE
 W
ES
TE
RN
 R
ES
ER
V
E 
U
N
IV
ER
SI
TY
 o
n 
22
/0
6/
20
15
 2
0:
15
:4
8.
 
View Article Online
View Journal
the membrane.28–30 As an alternative to cargo encapsulation
within a cell, there are also studies in which cargo molecules
have been bound covalently to erythrocyte membranes. Using
this technique, erythrocytes have specifically served to deliver
vaccine antigens, with delivery of HIV-1 TAT protein being a
key example.31,32
Gold nanoparticles with organic ligand shells are being
explored as candidate drug delivery agents that can carry drugs
sequestered within their organic layer, bound reversibly to the
gold core, or anchored to the ligand shell.33–36 Motivated by
the potential for such inorganic/organic hybrid nanomaterials
to carry therapeutics, here we characterized water-soluble
amphiphilic nanoparticles that partition into erythrocyte
membranes without the need for membrane perturbation or
manipulation, which we hypothesize could be loaded with
drugs for direct association with erythrocytes. Using a one-step
reaction, we synthesized small ∼2–4 nm core size gold nano-
particles (amph-AuNPs) with an amphiphilic ligand shell com-
prised of two alkanethiols.37 Each amph-AuNP was coated by a
mixture of long-chain mercaptoundecanesulfonate (MUS), an
eleven-carbon ligand terminated by a water-soluble sulfonate
group, and short-chain hydrophobic octanethiol (OT, Fig. 1a).
Our previous studies have shown that MUS : OT amph-AuNPs
can enter a variety of cells under conditions in which
endocytosis has been blocked.38–41 We have also shown that
they can carry oligonucleotide cargos into tumor cells under
these conditions.42 Notably, particle entry into cells was
observed without any experimental evidence of membrane
poration or disruption. These studies suggest that amph-
AuNPs can enter cells passively, likely via a membrane inter-
action, insertion, and/or penetration mechanism, which might
be applied to load cells with gold particles in a variety of
contexts.
Several studies have shown that AuNPs coated with a hydro-
phobic ligand shell can interact with and directly embed
within synthetic lipid bilayers.43–47 The basic mechanism put
forth in these studies is that the hydrophobic surface ligands
of the particles are able to closely associate with the hydro-
phobic interior of lipid bilayers, enabling stable particle
embedding within membranes. However, many of these
studies use entirely hydrophobic AuNPs that are insoluble in
water and, as a result, require the use of organic solvents to
drive AuNP–membrane interactions. A unique property of
amph-AuNPs is their environment-sensitive chemistry; in
water the sulfonate endgroups of the ligand shell impart solu-
bility, while ligand flexibility enables the hydrophobic octane-
thiol groups to be exposed during lipid membrane
interactions. The water solubility of amphAuNPs is essential
for their potential application for direct loading of cell mem-
branes in vivo. We have shown in previous work that the pres-
ence of 30–60% charged MUS ligand on amph-AuNPs imparts
water solubility and their anionic charge does not inhibit high
entry into dendritic cell or fibroblast membranes.38 Further,
we expect that charge–charge repulsion eﬀects between amph-
AuNPs and lipid headgroups are mitigated by screening at
physiological salt concentrations.
Previously, we tested the uptake of amph-AuNPs by RBCs
following brief incubations (1 h) at relatively low particle con-
centrations (0.1 mg mL−1), and were unable to detect particle
interactions with erythrocyte membranes.49 These results in
fact prompted us to develop an assay using RBCs to detect free
hydrophobic dye in labeled nanoparticle preparations, since
under these conditions free dye would immediately be absorbed
into the red cell membranes while particle-bound dye remained
in solution.49 However, in very recent work, computational
modeling in parallel with experimental studies using model
membranes suggested that these amph-AuNPs are not just
membrane-penetrating but actually thermodynamically prefer a
membrane-embedded state, where the hydrophilic sulfonate
headgroups in the amph-AuNP ligand shell ‘snorkel’ to the
aqueous/lipid interface much like transmembrane proteins to
achieve a state where free energy is minimized.48 These studies
further suggested that amph-AuNP embedding in membranes
is governed by NP core size and surface ligand composition
(e.g., hydrophobicity). These findings prompted us to revisit
the potential for interactions of amph-AuNPs with RBCs,
exploring in more detail particle localization relative to the
erythrocyte membrane as a function of NP concentration and
time, and the eﬀect of membrane composition itself on
NP–membrane interactions.
In this paper, we first present evidence, using multiple ana-
lysis techniques, of erythrocyte membrane-embedding by
MUS : OT AuNPs and characterize components of the erythro-
cyte membrane that influence particle insertion. Using the
results from this work, we then utilized well-defined giant mul-
tilamellar vesicles as model membranes to provide greater
insight into the role of membrane composition on particle
insertion. The results from this work inform the engineering
of these amphiphilic, membrane-embedding gold nano-
particles as potential drug carriers that might associate with
erythrocytes in vivo, without the need for preliminary ex vivo
manipulation.
Results & discussion
In previous work where we incubated amphiphilic MUS : OT
NPs with a 2 : 1 MUS : OT ligand ratio for 1 hour with erythro-
cytes, we detected no apparent interaction of the particles with
the cells.49 However, our recent combined experimental and
computational studies showed that particles with this compo-
sition and a gold core mean diameter of ∼2.3 embed within
model liposomal membranes to substantial levels,48 and
thus we revisited this experimental setting to determine if
RBCs have a particular surface structure that prevents NP
embedding or alternatively, if our lack of detecting particle
uptake was specific to the particular treatment conditions
tested. A key diﬀerence in the present study compared to our
previously published work49 is that here, as in our recent
model membrane experiments,48 cells were incubated with
particles for indicated times and immediately imaged live
without further manipulation. In contrast, in our earlier work
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Fig. 1 (a) MUS : OT amph-AuNP schematic detailing chemical structures of surface ligands. (b) Human erythrocytes incubated with BODIPY-MUS :
OT 2 : 1 amph-AuNPs at 0.28 mg mL−1 and calcein at 20 µg mL−1 for 3 h at 37 °C and imaged with a confocal microscope (scale bars on left panel
50 µm). (c, d) BODIPY-MUS : OT 2 : 1 NPs at 0.28 mg mL−1 were incubated with erythrocytes at 4 °C, 22 °C, and 37 °C for 3 h, and interaction was
analyzed by ﬂow cytometry (c), and quantiﬁed (error bars for standard error of the mean, SEM; signiﬁcance noted directly above columns indicates
value of that column relative to untreated control) (d). Statistics were performed with a one-way ANOVA test, followed by Tukey’s multiple compari-
son test (P < 0.05 is signiﬁcant, *** indicates P < 0.0001). (e) Kinetics of BODIPY-MUS : OT 2 : 1 AuNPs at 0.07 mg mL−1 association with erythrocytes
over 24 h at 37 °C (error bars for SEM). All experiments were performed with at least 3 biological replicates per condition.
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using RBCs as a ‘free dye sensor’, cells were washed thoroughly
at least three times before analysis.49 Given our current under-
standing that amph-AuNPs passively, reversibly, and fluidly
insert into membranes, it is reasonable to expect that repeated
centrifugation and buﬀer exchange due to multiple washings
might extract membrane-embedded amph-AuNPs back into
solution. In the present study, unless cells were fixed first (as
for electron microscopy), cells were not washed to remove
excess amph-AuNPs after incubation. For these experiments,
particles were incubated with cells in PBS (for short-term
assays 1–3 h) or complete medium (RPMI supplemented with
the RBC-specific serum replacement Albumax, for long-term
assays >3 h). We observed no significant diﬀerences in amph-
AuNP interactions with RBC membranes when comparing
uptake in these two treatment conditions. This result is con-
sistent with our previous measurements, which showed that
amph-NPs are highly resistant to protein adsorption; dynamic
light scattering (DLS), TEM, and zeta potential analysis all con-
firmed that there were no changes in amph-AuNP size or
charge when incubated in medium with and without serum.38
We prepared 2 : 1 MUS : OT amph-AuNPs 2.3 ± 1.0 (st. dev.)
nm in diameter (batch A, Fig. 1a, ESI Fig. 1a & ESI Table 1†)
labeled with an alkanethiol-BODIPY fluorescent dye by a place
exchange reaction to track the particles’ interactions with cells
as previously described.49 When human erythrocytes were co-
incubated with the membrane-impermeable dye calcein and
BODIPY-labeled amph-AuNPs at 37 °C for 3 hours, confocal
micrographs showed that calcein remained extracellular, but
the gold particles distinctly associated with the plasma mem-
branes of the cells (Fig. 1b). This particle signal was low but
clearly detectable, and appeared confined to the plasma mem-
brane of the RBCs. Lack of calcein entry into the RBCs indi-
cates that particle binding to the cells was not associated with
membrane disruption. Analysis of MUS : OT-treated erythro-
cytes by flow cytometry at 4 °C, 22 °C, and 37 °C, showed clear
temperature-dependent binding, which was highest at 37 °C
(9-fold compared to untreated cells, Fig. 1c and d). Analysis of
the kinetics of amph-AuNP binding to RBCs showed that
MUS : OT AuNPs (batch B with core size of 2.4 ± 0.8 nm, ESI
Fig. 1b & ESI Table 1†) associated with erythrocytes as quickly
as 5 min at 37 °C, with particle uptake increasing rapidly over
the first 3 hours and continuing over 24 h albeit more gradu-
ally (Fig. 1e). To assay for the stability of amph-AuNP incorpor-
ation into RBC membranes, we compared amph-AuNP signal
associated with cells after serial washing steps (ESI Fig. 2†).
Signal decreased by ∼30% after one washing step in PBS and
did not statistically decrease further after three washes. Even
after washing, however, amph-AuNP signal remained signifi-
cantly above background.
We next compared the behavior of these anionic amph-
AuNPs to the interaction of amphiphilic gold nanoparticles
bearing a cationic charge. Cationic amph-AuNPs coated with
eleven-carbon alkanethiol ligands terminated by trimethyl-
amine (TMA) groups were prepared with a gold core diameter
of 5.7 ± 1.5 nm. In clear contrast to the sulfonate-functiona-
lized amph-AuNPs (Fig. 1b), BODIPY-labeled TMA AuNPs
aggregated significantly on and around erythrocytes, reminis-
cent of the aggregation reported by Li and Malmstadt for cat-
ionic particles that bind to and then extract protrusions of
membrane lipids in contact with giant lipid vesicles (ESI
Fig. 3†).50 In addition, incubation with TMA amph-AuNPs led
to calcein leakage into many cells (ESI Fig. 3† arrows), indicat-
ing that the cationic nanoparticles induced membrane pora-
tion. Since TMA particles are known to disrupt cell
membranes by virtue of their cationic charge,51,52 it is likely
that their charge and not their larger size was responsible for
RBC membrane poration. In our previous work, we observed
similar membrane disruption in dendritic cells treated with
TMA particles of core sizes similar to amph-AuNPs.38
The confocal analysis indicated that MUS : OT NPs appear
to prefer a membrane-associated state and, since erythrocytes
lack a nucleus or internal membranes, it is noteworthy that
amph-AuNPs outlined the only cellular membrane present, the
plasma membrane. To confirm these observations at the light
microcopy level and rule out potential eﬀects of the dye itself,
we treated erythrocytes with unlabeled 1 : 1 MUS : OT NPs of a
2.1 ± 0.8 nm core size (batch C, ESI Fig. 1c & ESI Table 1†) for
either 1 h or 16 h at 37 °C, then fixed, embedded, and sec-
tioned them for electron microscopy (Fig. 2). At both time
points, AuNPs were distinctly found associated with the cell
surfaces, either directly opposed to the membrane or appar-
ently embedded within it (Fig. 2a and b). Distinctly, no par-
ticles were found in the cytosol for either time point (Fig. 2c).
Further, at the highest resolution that we could achieve, it
appeared that most of the MUS : OT NPs that decorated the
membrane were embedded within it.
Given this confirmation that amph-AuNPs associate with
RBCs, we next sought to determine the features of the cell
surface that play a role in mediating AuNP–membrane inter-
action. Since erythrocytes are non-nucleated and free of other
organelles, their plasma membrane has a key role in regulating
both the structure and function of the entire cell. The erythro-
cyte membrane, which has been very well studied,53,54 is made
up of three components (Fig. 3). First, there is a dense glyco-
calyx on the external face, composed of the polysaccharide
chains of glycolipids and glycoproteins capped by sialic acid
molecules, which contribute to an overall negative charge.
They are the first point of contact with other cells and any
interacting nanomaterials. Second, the lipid bilayer of the
membrane itself is composed of lipids and cholesterol and
also up to 50% by mass of proteins, many of which have trans-
membrane domains. Third and finally, the spectrin–actin
network of the underlying cytoskeleton is intimately and
strongly associated with the membrane, creating a tension that
controls an erythrocyte’s unique mechanical properties that
allow it to travel through the myriad vessels of the body’s circu-
latory system. We sought to characterize the role of each of
these three contributors to RBC surface properties in turn by
treating RBCs with enzymes or inhibitors to remove or alter
the function of diﬀerent membrane components. For each
condition, after enzymatic or drug treatment (Fig. 3), treat-
ment medium was removed, and cells were then incubated
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with BODIPY-labeled 2 : 1 MUS : OT NPs (batch B, 2.4 nm core
size) for 1–2 h before analysis of particle association with the
cells by flow cytometry.
To study the eﬀect of the glycocalyx on MUS : OT inter-
actions with the membrane, erythrocytes were treated either
with neuraminidase to selectively remove only the sialic acids,
or with a combination of neuraminidase, heparinase, and
hyaluronidase to remove the entire sugar layer on the surface
of the cells.55,56 When sialic acids were preferentially stripped,
MUS : OT interactions increased significantly (2.2-fold) com-
pared to unaltered cells treated with AuNPs, suggesting that
the interaction of the anionic particles with the RBC mem-
brane is substantially inhibited by these negatively-charged
sugars (Fig. 4a). When the entire glycocalyx was removed,
MUS : OT-membrane interaction increased only slightly further
(2.6-fold compared to unaltered cells) (Fig. 4a), suggesting
that the repulsive negative charge (contributed by the sialic
acids) likely plays a bigger role in modulating AuNP–mem-
brane interactions than steric eﬀects contributed by the
entire glycocalyx sugar brush. We also stripped the glyco-
calyx of erythrocytes, held them at 37 °C, and treated them
for 50 min with unlabeled 1 : 1 MUS : OT AuNPs with a
Fig. 2 Erythrocytes treated with unlabeled 1 : 1 MUS : OT amph-AuNPs (batch C) for 16 h at 37 °C were ﬁxed and sectioned for TEM imaging. Scale
bars 200 nm for (a) and (b), and 100 nm for (c).
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2.1 nm core (batch C), and then fixed and prepared them
for electron microscopy. As shown in Fig. 4d, in agreement
with the flow cytometry analysis, amph-AuNPs showed high
density embedding in glycocalyx-stripped erythrocyte mem-
branes. Notably, even with the glycocalyx stripped, the elec-
tron micrographs showed that all NPs found were
apparently membrane-associated and none were found in
the cytosol of cells. When erythrocytes were treated with
trypsin and chymotrypsin to remove membrane glyco-
proteins (chiefly of the glycophorin family55–57), there was
no significant diﬀerence in AuNP–membrane interaction fol-
lowing this treatment (Fig. 4b). Collectively, these results
suggest that the cell surface association observed by con-
focal and electron microscopy reflects favorable particle
interactions with the cell membrane itself rather than with
cell surface proteins or components of the glycocalyx.
We next tested the role of cytoskeletal–membrane tension
on MUS : OT particle interactions with the RBC membrane, by
treating RBCs with iodoacetamide and inosine to deplete ATP
and thus increase cytoskeletal–membrane tension, or by treat-
ing the cells with calyculin A and phorbol 12-myristate 13-
acetate (PMA) to activate protein kinase C (PKC), disrupt the
spectrin–actin network, and decrease this tension.58,59 There
was no diﬀerence in particle association by cells when ATP was
depleted to increase tension, but association increased by 1.6-
fold when the spectrin–actin network was disrupted to
decrease tension (Fig. 4c). Since the drugs for this latter treat-
ment were introduced in DMSO, we also treated cells with
amph-AuNPs in the presence of the same concentration of
DMSO (1 vol%) alone, and saw no eﬀect of the vehicle alone
(data not shown). Thus, amph-AuNPs may prefer bilayer areas
where cytoskeletal–membrane tension is low.
These experiments with erythrocytes indicated that the
surface glycocalyx and charge play significant roles in amph-
AuNP/membrane interactions, but the living cell has a highly
complex surface structure where many components may simul-
taneously participate in governing the outcome of nanoparticle
binding. Thus, we next moved to a synthetic system of model
membranes to better understand and confirm the roles of
specific cell surface lipids and sugars on amph-AuNP/mem-
brane association. We prepared giant multilamellar vesicles
(GMVs) composed of synthetic lipids by gentle hydration.48
The composition of the erythrocyte membrane has been
widely studied and its outer leaflet is composed of phospho-
lipids (glycerophospholipids and sphingomyelin), glycosphin-
golipids (making up the glycocalyx), and cholesterol.60,61
GMVs were prepared with a composition of 30.5% phospha-
tidylcholine (DOPC), 27% sphingomyelin (SM), 25% chole-
sterol, 7% phosphatydilethanolamine (DOPE), and 10%
ganglioside GM1, mimicking the outer leaflet of the RBC
membrane60–62 (Fig. 5a). 0.5 mol% 7-nitro-2-1,3-benzoxadiazol-
4-yl (NBD)-DOPE was also included as a fluorescent tag for the
membranes. GM1, which makes up part of the glycocalyx, has
one sugar branch terminated by a sialic acid, and SM has a
high melting temperature (Tm) of 37–41 °C.
63,64 BODIPY-
labeled 2 : 1 MUS : OT amph-AuNPs with a 2.4 nm core
(batch B) were incubated with these RBC-mimic GMVs or
control fluorescently-tagged DOPC-only GMVs for 1 h at room
temperature and then imaged by confocal microscopy. We pre-
viously showed by confocal microscopy that amph-AuNPs
absorb spontaneously into DOPC GMVs, with particles pene-
trating throughout multilamellar vesicles;48 this result was
again observed here with labeled DOPC GMVs (Fig. 5b). By
contrast, consistent with the low levels of particle uptake
observed for native RBCs at this particle dose and temperature
(Fig. 1c and d), little or no embedding of amph-AuNPs in
erythrocyte outer leaflet mimic GMVs was observed (Fig. 5b).
To determine which component(s) of the RBC mimic
bilayers were critical for inhibiting particle embedding/pene-
tration relative to simple DOPC membranes, we incrementally
added one outer leaflet lipid at a time to DOPC GMVs and
measured AuNP uptake by flow cytometry. Compared to the
all-DOPC GMVs, AuNP–membrane interactions decreased 34%
when cholesterol was added, but further addition of DOPE or
Fig. 3 Schematic diagramming erythrocyte membrane components and treatment methods used to perturb them.
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sphingomyelin had little further impact on particle absorption
by the GMVs (BODIPY-labeled 2 : 1 MUS : OT NPs from batch
B, Fig. 5c). However, upon introduction of the ganglioside
lipid GM1, there was an additional substantial drop in AuNP
uptake, giving in total a 92% decrease in AuNP absorption
compared with DOPC GMVs. We next prepared a series of
seven GMV formulations with pairwise combinations of indi-
vidual RBC membrane components added in their natural pro-
portion: all DOPC, DOPC/15% DOPE, DOPC/25% cholesterol,
DOPC/16% SM, DOPC/10% GM1. GMVs were incubated for
1 h with BODIPY-labeled 2 : 1 MUS : OT NPs (batch B, Fig. 5d).
Compared to the DOPC GMVs, there were decreases in AuNP–
membrane interaction in the cases of high Tm SM and nega-
tively-charged GM1. However, this decrease in signal was sig-
nificant only in the case of GM1, where interaction decreased
by 65% compared to the all-DOPC formulation. These results
further support our conclusions that the glycocalyx has a
central role in modulation of AuNP–membrane interactions.
Finally, to assess the eﬀect of temperature on these inter-
actions, we compared amph-AuNP uptake in sphingomyelin-
or GM1-containing GMVs at 22 °C and 37 °C (Fig. 5e). We com-
pared these to all-DOPC GMVs incubated with amph-AuNPs at
22 °C as a ‘gold standard’ for GMVs absorbing high levels of
amphiphilic particles. GMVs containing SM but lacking GM1
showed lower particle absorption at 22 °C compared to the
DOPC control vesicles, but at 37 °C, which is at the Tm of SM,
Fig. 4 (a–c) RBCs were incubated with BODIPY-MUS : OT 2 : 1 amph-AuNPs (batch B, 0.08 mg mL−1) for 1 h at 22 °C and then analyzed for nano-
particle association by ﬂow cytometry. (a) RBCs were treated with enzymes removing sialic acids or the entire glycocalyx prior to NP incubation. (b)
RBCs were treated with trypsin and chymotrypsin to remove cell surface glycoproteins prior to NP incubation. (c) RBCs were treated with drugs
increasing or decreasing membrane tension prior to NP incubation. Statistics were performed with a one-way ANOVA test, followed by Bonferroni’s
multiple comparison test (P < 0.05 is signiﬁcant, *** indicates P < 0.0001). All experiments were performed with at least 3 biological replicates per
condition. (d) Cell electron micrograph of unlabeled 1 : 1 MUS : OT amph-AuNPs (batch C, incubated for 1 h at 37 °C) as they interacted with erythro-
cytes that had their glycocalyx stripped, scale bar 200 nm.
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Fig. 5 (a) Synthetic lipids used to make model erythrocyte membranes. (b) Confocal micrographs of all-DOPC GMVs and erythrocyte outer leaﬂet
GMVs treated with BODIPY-MUS : OT 2 : 1 amph-AuNPs (batch B, 0.07 mg mL−1) for 1 h at 22 °C, scale bars 50 µm. (c, d) Amph-AuNPs (batch B,
0.07 mg mL−1) were incubated with incremental GMV formulations (c) or GMVs incorporating individual membrane components (d) for 1 h at 22 °C,
and analyzed for NP/membrane association by ﬂow cytometry. Median ﬂuorescence intensities of particles associated with GMVs (error bars for
SEM between individual biological replicates). In (c), signiﬁcance noted directly above columns is compared to the DOPC/DOPE/chol/SM/GM1 case.
In (d), signiﬁcance noted directly above columns is compared to the all-DOPC case. (e) Amph-AuNPs (batch B, 0.07 mg mL−1) incubated with GMVs
with or without GM1 present at 22 °C and 37 °C and assessed after 1 h by ﬂow cytometry. Signiﬁcance noted directly above columns is compared to
the all-DOPC case (22 °C). Statistics were performed with a one-way ANOVA test, followed by Tukey’s multiple comparison test (P < 0.05 is signiﬁ-
cant, *** indicates P < 0.0001). All experiments were performed with at least 3 biological replicates per condition.
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amph-AuNP absorption to the membrane-mimic GMVs was
comparable to DOPC controls. By contrast, RBC membrane
mimics including GM1 showed a substantially lower increase
in particle association that increased only 2.4-fold moving
from 22 °C to 37 °C, consistent with our whole-cell experi-
ments that suggested the glycocalyx plays an important role in
limiting nanoparticle absorption into the cell plasma mem-
brane. Therefore, we conclude that, while increasing tempera-
ture to the physiological range overcomes the particle-blocking
eﬀect of SM, it has only a small influence on the eﬀect of GM1.
These results suggest that while erythrocyte membrane decora-
tion may be wholly suﬃcient with a glycocalyx intact, perhaps
co-administration of neuraminidase (or similar sialic acid-alter-
ing molecule) attached to the nanoparticle could be employed
to achieve higher levels of NP–membrane interactions.
Conclusions
Employing erythrocytes as ‘pharmacytes’ – cell-based carriers
of therapeutic cargoes – is of great interest, but current tech-
niques first require manipulation of cells ex vivo before auto-
logous transfer in vivo. Here, we present a system of
amphiphilic AuNPs that, by virtue of their core size and
surface ligand hydrophobicity, are able to embed within eryth-
rocyte membranes. We have shown that amph-AuNP-mem-
brane embedding depends on membrane fluidity and the
glycocalyx, and particle association with RBC membranes is
promoted by increasing temperature (up to physiological
levels) or when the glycocalyx in general or the sialic acids in
particular are removed. Our studies with model lipid mem-
branes further suggest that the high Tm lipid SM plays a key
role in modulating amph-AuNP association with RBC mem-
branes at room temperature but GM1 plays a more important
role at physiological temperature. These results inform design
characteristics needed to achieve optimal membrane-embed-
ding by amphiphilic nanoparticles. Altogether, these results
suggest that these amph-AuNPs may be useful as drug carriers
that may mediate easy and rapid embedding into erythrocyte
membranes in vivo without the need for ex vivo manipulation.
Experimental
Materials
HAuCl4 salt, OT ligand, and calcein were purchased from
Sigma. BODIPY 630/650-X succinimidyl ester was purchased
from Invitrogen. MUS ligands were prepared in-house with a
method described previously.38 Amph-AuNPs were also pre-
pared in-house as described previously.37 Neuraminidase,
hyaluronidase, and heparinase were purchased from Sigma, as
were trypsin and chymo-trypsin. Calyculin A, phorbol 12-myris-
tate 13-acetate (PMA), iodoacetamide, and inosine were also
purchased from Sigma. All lipids and cholesterol were pur-
chased from Avanti Polar Lipids.
AuNP synthesis, characterization, & labeling
We used a modified one-phase Brust–Schiﬀrin synthesis to
prepare amph-AuNPs.65 Briefly, a solution of HAuCl4 was pre-
pared in ∼200 mL ethanol and an equimolar mixture of thiol
ligands was prepared in methanol. These two solutions were
mixed together and allowed to stir for 15 min. A saturated solu-
tion of NaBH4 in ethanol was then added slowly and drop-wise
and, following this step, the reaction was allowed to stir for an
additional 3 h. The flask was placed at 4 °C overnight after
which the precipitated particles were isolated by filtration
through qualitative filter paper. The filtered particles were
washed sequentially in ethanol and methanol and dried with
further washes in acetone. Before characterization or analysis,
insoluble NPs were first removed by dissolving ∼10 mg dry
NPs in 1 mL water, centrifuging at 14 000g for 2 min, and iso-
lating the soluble NPs that remain in the supernatant. Size dis-
tributions of NP batches were determined using transmission
electron microscopy (TEM). ImageJ software was used to quan-
tify the sizes of NPs from high magnification TEM images,
which were subsequently used to calculate the mass extinction
coeﬃcient.
A BODIPY-C11-SH dye construct was prepared in-house by
adding an alkylthiol linker to BODIPY 630/650-X, succinimidyl
ester. Amph-AuNPs were labeled by place-exchange of
BODIPY-C11-SH with surface ligands by incubating 30 µmoles
of dye construct per mg of NPs over 2–4 days at 22 °C with con-
stant shaking or stirring. Labeled AuNPs were purified and
separated from excess dye by precipitation and washing in
acetone at least 5×. Washed amph-AuNPs were dried overnight
and solubilized in water for use.
Erythrocyte preparation, enzyme treatment, & incubation with
amph-AuNPs
Human erythrocytes were stored in packed volume at 4 °C.
Prior to use, 200 µL of packed erythrocytes were washed 3× in
1 mL PBS or complete RPMI with Albumax, and finally resus-
pended in 1 mL PBS/medium for use. To prepare experimental
samples, 2–4 µL of this cell stock (4–8 million cells) were used
per sample. Amph-AuNP concentrations of 0.07, 0.14, and
0.28 mg mL−1 were used for incubation times of 1–3 h at 4 °C,
22 °C, and 37 °C where necessary. Prior to incubation at given
temperatures, erythrocytes were pre-incubated by a ∼20 min
equilibration to the desired temperature before adding AuNPs.
For assaying uptake kinetics, erythrocytes were incubated at
0.07 mg mL−1 at 37 °C with continuous rotation. Fluorescence
was analyzed by flow cytometry without washing of excess
AuNPs at 5 min, 30 min, 1 h, 3 h, and 24 h. All erythrocytes
were obtained with approval by and in accordance with MIT
guidelines.
Stripping of sialic acids & glycocalyx. To selectively strip the
sialic acids oﬀ the surface of the membrane, erythrocytes were
treated with neuraminidase at 0.1 U mL−1 for 2 h at 22 °C with
continuous rotation. To strip the entire glycocalyx oﬀ the
surface of the membrane, erythrocytes were treated with a
combination of neuraminidase at 0.1 U mL−1, heparinase at
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5 U mL−1, and hyaluronidase at 50 µg mL−1 for 2 h at 22 °C
with continuous rotation. After treatment, cells were pelleted,
excess enzymes were removed, and amph-AuNPs were added.
Removal of membrane proteins. To remove membrane
glycoproteins, erythrocytes were co-treated with trypsin and
chymo-trypsin at 1 mg mL−1 each at 22 °C with continuous
rotation. After treatment, cells were pelleted, excess enzymes
were removed, and amph-AuNPs were added.
Increasing/decreasing cytoskeletal–membrane tension. To
deplete ATP and increase cytoskeletal–membrane tension,
erythrocytes were treated with a medium of 6 mM iodoaceta-
mine and 10 mM inosine in PBS without glucose for 3 h at
22 °C with continuous rotation. After treatment, cells were pel-
leted, and initial treatment volumes were removed. Amph-
AuNPs were then added in the same ATP depletion buﬀer.
To disrupt spectrin/actin networks and decrease cyto-
skeletal–membrane tension, erythroctyes were treated first
with 0.2 µM calyculin A for 30 min at 22 °C. Following this
incubation, cells were pelleted, treatment medium was
removed, and PMA was added for 90 min also at 22 °C.
Samples were rotated continuously during these incubations.
Finally, cells were pelleted, treatment volumes were removed,
and amph-AuNPs were added.
GMV synthesis & preparation
To synthesize GMVs, lipid stocks in chloroform were added to
glass scintillation vials, where total lipid was 1 µmole per vial.
When fluorescent lipid tracers were necessary to label GMVs,
dyes were added at 0.1–0.5 mol%. Chloroform was allowed to
evaporate overnight at 22 °C, in order to form lipid films on
glass. Uncapped vials were then incubated in a water bath at
70 °C for >6 h, and this step allowed these films to
hydrate without immersion in solution. Sucrose buﬀer (50 mM
in water or PBS) was then added at 2 mL per vial, and vials
were capped and further incubated at 70 °C overnight, allow-
ing GMVs to form. GMVs were gently harvested with minimal
agitation or mixing the following day, after first cooling
to 22 °C.
For the outer leaflet set (Fig. 5c), the following formulations
were used: (1) all-DOPC, (2) 75% DOPC/25% cholesterol, (3)
68% DOPC/7% DOPE/25% cholesterol, (4) 41% DOPC/7%
DOPE/25% cholesterol/27% SM, and (5) 31% DOPC/27% SM/
7% DOPE/25% cholesterol/10% GM1. For the pair-wise GMV
set (Fig. 5d), the following formulations were used: (1) all
DOPC, (2) DOPC/15% DOPE, (3) DOPC/25% cholesterol, (4)
DOPC/16% SM, and (5) DOPC/10% GM1.
Confocal microscopy
For erythrocytes, 4 million cells were added to 200 µL per well
of an 8-well LabTek chamber (Nunc). Calcein was added at
20 µg mL−1 and BODIPY-MUS : OT 2 : 1 amph-AuNPs were
added at 0.28 mg mL−1. Treatment medium was prepared
before the addition of cells and samples were rocked back and
forth gently without mixing or agitation with a pipette. Samples
were imaged with a LSM 510 confocal microscope (Carl Zeiss).
Z-Stacks were collected using an optical slice thickness of 1 µm,
and images were analyzed with Zeiss LSM software.
For GMVs, confocal samples were prepared in 8-well
LabTek chambers (Nunc) and, prior to adding GMVs, we first
prepared solutions of 50 mM glucose in water with
BODIPY-MUS : OT 2 : 1 amph-AuNPs at 0.07 mg mL−1. GMV
harvests in sucrose were mixed 1–2× with a pipette and added
at a 1 : 4 ratio in a sample well. Notably, samples were only
rocked back and forth after preparation and there was no
additional mixing of GMVs with AuNPs in the well. Samples
were incubated 1–3 h at 22 °C, unless otherwise noted.
Samples were then imaged with a LSM 510 confocal micro-
scope (Carl Zeiss). Z-Stacks were collected using an optical
slice thickness of 1 µm, and images were analyzed with Zeiss
LSM software.
Flow cytometry
For erythrocytes, 4–8 million cells were added per 200 µL per
round-bottom sample tube and either treated first with mem-
brane-perturbing enzymes (as described above) or with
BODIPY-labeled MUS : OT 2 : 1 amph-AuNPs at 0.07, 0.14, or
0.28 mg mL−1 for 1 h. Tubes were rotated continuously at a
desired incubation temperature. Samples from tubes were
transferred to 96-well round-bottom plates (BD) or polystyrene
flow cytometry tubes (BD Falcon) for analysis. Samples were
analyzed with a LSR Fortessa HTS flow cytometer (BD) and
data were analyzed using FlowJo software.
For GMVs, flow cytometry samples were prepared in 96-well
round-bottom plates (BD) or polystyrene flow cytometry tubes
(BD Falcon). We first prepared solutions of 50 mM sucrose in
water with BODIPY-MUS : OT 2 : 1 amph-AuNPs at 0.07 mg
mL−1 in sample wells. GMV harvests in sucrose were mixed
1–2× with a pipette and added at a 1 : 1.5 ratio per sample well.
Samples were rocked gently back and forth after preparation –
but there was no additional mixing of GMVs with AuNPs in
the wells. Samples were incubated at 1–3 h and 22 °C, unless
otherwise noted. Samples were then analyzed with a LSR For-
tessa HTS flow cytometer (BD) and data were analyzed using
FlowJo software.
Cell electron microscopy
For cell EM, cell fixative was first prepared as 2.5% gluteralde-
hyde, 3% paraformaldehyde with 5% sucrose in 0.1 M sodium
cacodylate buﬀer (pH 7.4). Since erythrocytes are in suspen-
sion, 200 µL of fixative was added to 200 µL sample volume,
rotated for 1 min at incubation temperature of 37 °C, pelleted,
and resuspended in 1 mL fixative. After fixing, cells were
pelletted, and post-fixed in 1% OsO4 in veronal-acetate buﬀer.
The cell pellet was stained in block overnight with 0.5% uranyl
acetate in veronal-acetate buﬀer (pH 6.0), then dehydrated and
embedded in Embed-812 resin. Sections were cut on a Reichert
Ultracut E microtome with a Diatome diamond knife at a
thickness setting of 50 nm. The sections were examined using
a FEI Tecnai Spirit at 80 KV and photographed with an AMT
CCD camera.
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